FAP and cancer: FAP inhibitors (FAPIs) labeled with radioactive tracers (68Ga, 18F, or 177Lu) are currently utilized in clinical practice for diagnosis and treatment in a wide range of malignant tumors and their associated metastases, demonstrating significant superiority over 18F-fluoro-2-deoxy-D-glucose (18F-FDG) in certain contexts.